Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive

Contraception

Volumn 93, Issue 1, 2016, Pages 52-57

  Nakajima, Steven T ^a   Pappadakis, Jennifer ^b   Archer, David F ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Actavis Inc   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Ethinyl estradiol; Norethindrone acetate; Obesity; Oral contraceptive; Weight

Indexed keywords

ETHINYLESTRADIOL; NORETHISTERONE ACETATE; ESTROGEN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; BREAST TENDERNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; METRORRHAGIA; MULTICENTER STUDY (TOPIC); NAUSEA; OBESITY; OPEN STUDY; ORAL CONTRACEPTION; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RHINOPHARYNGITIS; SINUSITIS; SPOTTING; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS; WITHDRAWAL BLEEDING; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREGNANCY; UNPLANNED PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; AMENORRHEA; BODY MASS INDEX; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUATION; METRORRHAGIA; MIDDLE AGED; NORETHINDRONE; OBESITY; PREGNANCY; PREGNANCY, UNPLANNED; YOUNG ADULT;

EID: 84951105048     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2015.09.013     Document Type: Article

References (35)

1. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of childhood and adult obesity in the United States, 2011-2012 JAMA 311 2014 806 814
2. M. Abdollahi, M. Cushman, and F.R. Rosendaal Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use Thromb Haemost 89 2003 493 498
3. L.A. Heinemann, and J.C. Dinger Range of published estimates of venous thromboembolism incidence in young women Contraception 75 2007 328 336
4. Group E.C.W. Venous thromboembolism in women: a specific reproductive health risk Hum Reprod Update 19 2013 471 482
5. A.A. Djelantik, A.E. Kunst, M.F. van der Wal, H.A. Smit, and T.G. Vrijkotte Contribution of overweight and obesity to the occurrence of adverse pregnancy outcomes in a multi-ethnic cohort: population attributive fractions for Amsterdam BJOG 119 2012 283 290
6. R.J. Van Lieshout, V.H. Taylor, and M.H. Boyle Pre-pregnancy and pregnancy obesity and neurodevelopmental outcomes in offspring: a systematic review Obes Rev 12 2011 e548 e559
7. S. Joy, N. Istwan, D. Rhea, C. Desch, and G. Stanziano The impact of maternal obesity on the incidence of adverse pregnancy outcomes in high-risk term pregnancies Am J Perinatol 26 2009 345 349
8. M.F. Gallo, K. Nanda, D.A. Grimes, L.M. Lopez, and K.F. Schulz 20 microg versus > 20 microg estrogen combined oral contraceptives for contraception Cochrane Database Syst Rev 2011 CD003989
9. O. Lidegaard, E. Lokkegaard, A. Jensen, C.W. Skovlund, and N. Keiding Thrombotic stroke and myocardial infarction with hormonal contraception N Engl J Med 366 2012 2257 2266
10. R.T. Burkman Oral contraceptives: current status Clin Obstet Gynecol 44 2001 62 72
11. J. Dinger, T.D. Minh, N. Buttmann, and K. Bardenheuer Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen Obstet Gynecol 117 2011 33 40
12. D.F. Archer, S.T. Nakajima, A.T. Sawyer, J. Wentworth, S. Tupin, W.D. Koltun, and et al. A Novel Ultra-Low-Dose Oral Contraceptive: 1.0 mg Norethindrone Acetate/10 μg Ethinyl Estradiol Obstet Gynecol 122 2013 601 607
13. C.L. Westhoff, H.I. Hait, and K.Z. Reape Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive Contraception 85 2012 235 239
14. H.F. Zhang, K.D. LaGuardia, and D.L. Creanga Higher body weight and body mass index are not associated with reduced efficacy in Ortho Tri-Cyclen Lo users Obstet Gynecol 107 2006 50S
15. L.R. Brunner Huber, and J.L. Toth Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth Am J Epidemiol 166 2007 1306 1311
16. L.R. Brunner, and C.J. Hogue The role of body weight in oral contraceptive failure: results from the 1995 national survey of family growth Ann Epidemiol 15 2005 492 499
17. M. Vessey Oral contraceptive failures and body weight: findings in a large cohort study J Fam Plann Reprod Health Care 27 2001 90 91
18. R.T. Burkman, A.C. Fisher, G.J. Wan, C.E. Barnowski, and K.D. LaGuardia Association between efficacy and body weight or body mass index for two low-dose oral contraceptives Contraception 79 2009 424 427
19. L.R. Brunner Huber, C.J. Hogue, A.D. Stein, C. Drews, and M. Zieman Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina Ann Epidemiol 16 2006 637 643
20. C. McNicholas, Q. Zhao, G. Secura, J.E. Allsworth, T. Madden, and J.F. Peipert Contraceptive failures in overweight and obese combined hormonal contraceptive users Obstet Gynecol 121 2013 585 592
21. V.L. Holt, K.L. Cushing-Haugen, and J.R. Daling Body weight and risk of oral contraceptive failure Obstet Gynecol 99 2002 820 827
22. V.L. Holt, D. Scholes, K.G. Wicklund, K.L. Cushing-Haugen, and J.R. Daling Body mass index, weight, and oral contraceptive failure risk Obstet Gynecol 105 2005 46 52
23. M.D. Creinin, and E. Roberts Body mass index, weight, and oral contraceptive failure risk Obstet Gynecol 105 2005 1492 [author reply-3]
24. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, M.C. Pike, and F.Z. Stanczyk Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women Contraception 81 2010 474 480
25. A.B. Edelman, G. Cherala, M.Y. Munar, M. McInnis, F.Z. Stanczyk, and J.T. Jensen Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial Contraception 90 2014 550 556
26. A.R. Baerwald, O.A. Olatunbosun, and R.A. Pierson Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use Contraception 70 2004 371 377
27. C. Klipping, I. Duijkers, D. Trummer, and J. Marr Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen Contraception 78 2008 16 25
28. S.T. Nakajima, D.F. Archer, and H. Ellman Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe) Contraception 75 2007 16 22
29. D.R. Mishell Jr., J. Guillebaud, C. Westhoff, A.L. Nelson, A.M. Kaunitz, J. Trussell, and et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception Contraception 75 2007 4 10
30. M.J. Rosenberg, M.S. Waugh, and T.E. Meehan Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation Contraception 51 1995 283 288
31. M.J. Rosenberg, and M.S. Waugh Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons Am J Obstet Gynecol 179 1998 577 582
32. A.L. Nelson, C. Westhoff, and S.M. Schnare Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation Obstet Gynecol 112 2008 782 787
33. C.L. Westhoff, S. Heartwell, S. Edwards, M. Zieman, G. Stuart, C. Cwiak, and et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 196 2007 412.e1 412.e7 [discussion e6-7]
34. C.L. Ogden, M.M. Lamb, M.D. Carroll, and K.M. Flegal Obesity and socioeconomic status in adults: United States NCHS Data Brief 2010 2005-2008 1 8
35. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of obesity in the United States NCHS Data Brief 2012 2009-2010 1 8